Goutham Narla
Affiliations: | Cancer Biology | Icahn School of Medicine at Mount Sinai, New York, NY, United States |
Area:
Molecular Biology, Cell Biology, Genetics, OncologyGoogle:
"Goutham Narla"Children
Sign in to add trainee| Raheleh Hatami | grad student | 2012 | Mount Sinai |
| Jaya Sangodkar | grad student | 2012 | Mount Sinai School of Medicine |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Izadmehr S, Fernandez-Hernandez H, Wiredja D, et al. (2024) Cooperativity of c-MYC with Krüppel-Like Factor 6 Splice Variant 1 induces phenotypic plasticity and promotes prostate cancer progression and metastasis. Biorxiv : the Preprint Server For Biology |
| Rasool RU, O'Connor CM, Das CK, et al. (2023) Loss of LCMT1 and biased protein phosphatase 2A heterotrimerization drive prostate cancer progression and therapy resistance. Nature Communications. 14: 5253 |
| Peris I, Romero-Murillo S, Vicente C, et al. (2023) Regulation and role of the PP2A-B56 holoenzyme family in cancer. Biochimica Et Biophysica Acta. Reviews On Cancer. 1878: 188953 |
| Avelar RA, Armstrong AJ, Carvette G, et al. (2023) Small molecule mediated stabilization of PP2A modulates the Homologous Recombination pathway and potentiates DNA damage-induced cell death. Molecular Cancer Therapeutics |
| Shatat MA, Gauthier B, Yoon S, et al. (2022) Mistletoe lectin inhibits growth of Myc-amplified small-cell lung cancer. Cancer Medicine |
| Peris I, Romero-Murillo S, Martínez-Balsalobre E, et al. (2022) Activation of the PP2A-B56α heterocomplex synergizes with venetoclax therapies in AML through BCL2 and MCL1 modulation. Blood |
| Haanen TJ, O'Connor CM, Narla G. (2022) Biased holoenzyme assembly of Protein Phosphatase 2A (PP2A): from cancer to small molecules. The Journal of Biological Chemistry. 102656 |
| O'Connor CM, Taylor SE, Miller KM, et al. (2021) Targeting ribonucleotide reductase induces synthetic lethality in PP2A-deficient uterine serous carcinoma. Cancer Research |
| Brautigan DL, Farrington C, Narla G. (2021) Targeting protein phosphatase PP2A for cancer therapy: development of allosteric pharmaceutical agents. Clinical Science (London, England : 1979). 135: 1545-1556 |
| Laine A, Nagelli SG, Farrington C, et al. (2021) CIP2A interacts with TopBP1 and drives basal-like breast cancer tumorigenesis. Cancer Research |